Laurie Grier, MD
Critical Care Medicine · Shreveport, LANPI 1679595011
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (45.0%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 30 manufacturers reported payments, led by La Jolla Pharmaceutical Company at 46.4% of the total. Reporting peaked in 2019 at $13,484 and has fallen 86.6% since, to $1,811 in 2025. Among critical care medicine clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 500 payments — averaging $45.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- La Jolla Pharmaceutical Company$11K
- Edwards Lifesciences$3K
- AstraZeneca$2K
- Actelion Pharmaceuticals US, Inc.$1K
- Boehringer Ingelheim$835
- Merck$714
- plus $4K from 24 others
What the payments were for
- Consulting fees$3,25414%
- Speaking & faculty fees$10,21145%
- Travel & lodging$5442%
- Food & beverage$8,66138%
- Education$90%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| La Jolla Pharmaceutical Company | 17 | $10,531 |
| Edwards Lifesciences | 8 | $3,409 |
| AstraZeneca(2 entities) | 95 | $1,863 |
| Actelion Pharmaceuticals US, Inc. | 114 | $1,410 |
| Boehringer Ingelheim | 40 | $835 |
| Merck | 46 | $714 |
| GSK | 39 | $613 |
| Johnson & Johnson | 30 | $466 |
| Insmed, Inc. | 27 | $433 |
| Baxter Healthcare | 3 | $351 |
| BD | 3 | $324 |
| Bard Access Systems, Inc. | 1 | $300 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $227 |
| Pfizer | 11 | $194 |
| E.r. Squibb & Sons, L.L.C. | 14 | $183 |
| Abiomed | 2 | $126 |
| Grifols USA, LLC | 6 | $125 |
| Regeneron Healthcare Solutions, Inc. | 5 | $99 |
| Bayer | 4 | $75 |
| Sanofi | 4 | $74 |
| Mallinckrodt Hospital Products Inc. | 4 | $71 |
| Gilead | 4 | $70 |
| Genentech USA, Inc. | 2 | $38 |
| Shionogi Inc | 2 | $34 |
| Pinnacle Biologics, Inc | 1 | $28 |
| Sandoz | 1 | $22 |
| Resmed Corp | 1 | $20 |
| Paratek Pharmaceuticals, Inc. | 1 | $17 |
| Verona Pharma, Inc. | 1 | $15 |
| Shire North American Group Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GIAPREZA$10,342
- HemoSphere$525
- Non-Franchise (NOF) - NonProduct$204
- LOKELMA$125
- Impella$108
How this compares
$22,679 in reported general payments places this provider in the 95th percentile of 72 critical care medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other critical care medicine in Shreveport
- Richard MorrisonShreveport$24K
- Jonathan EatonShreveport$19K
- Steven ConradShreveport$15K
- Cory MarkhamShreveport$3K
- Christopher TrosclairShreveport$3K
- Sukhmani BoparaiShreveport$2K
- Taylor ConradShreveport$2K
- Kevin LangloisShreveport$2K
- Aiyasawmy DorairajanShreveport$2K
- Ajit AlexanderShreveport$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.